



Atara Biotherapeutics  
 Investor Relations Department  
 701 Gateway Blvd, Suite 200  
 South San Francisco, CA 94080  
 United States

Visit IR website [↗](#)  
 Sign-up for Email alerts [↗](#)

#### NASDAQ: ATRA

Last Trade:	14.40
Trade Time:	4:00 PM ET Jun 28, 2017
Change:	0.40 <span style="color: green;">▲</span> (+2.857%)
Day Range	13.75 - 14.75
52-Week Range	11.80 - 25.73
Volume	323,797


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Atara Biotherapeutics, Inc. is a biotechnology company developing T-cell immunotherapies for patients with severe and life-threatening diseases who have been underserved by scientific innovation, with a focus on cancer and autoimmune and infectious diseases.

Atara's "Off-the-Shelf" allogeneic T-cell immunotherapy platform harnesses the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. Atara's most advanced product candidate, ATA129, for cancer patients with rituximab refractory Epstein-Barr virus (EBV)... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- May 24, 2017*  
[Atara Biotherapeutics to Present at Three Upcoming Investor Conferences](#)
- May 10, 2017*  
[Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- May 10, 2017*  
[Atara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team](#)
- May 4, 2017*  
[Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights](#)

### Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Mar 9, 2017*  
[Annual Report \(10-K\)](#)
- Apr 25, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- May 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*  
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2016*  
[Quarterly Report \(10-Q\)](#)